This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Global Pharmaceutical Leader Chooses Acsis Enterprise Serialization Management Suite To Achieve E-Pedigree Compliance

MARLTON, N.J., April 9, 2013 /PRNewswire/ -- Acsis Inc., the market leader for Enterprise Serialization solutions, today announced Daiichi Sankyo, Inc. selected the Acsis Serialization Management Suite to comply with FDA e-pedigree mandates and other federal regulations. The turnkey solution includes the Acsis proven serialization management solution with best-of-breed vision and printing equipment from Cognex and Domino. Daiichi Sankyo will install this turnkey solution initially as a pilot at the company's packaging plant in Bethlehem, PA, with Acsis managing all aspects of implementation and support. 

The Acsis serialization solution for Daiichi Sankyo ensures the protection of the company's pharmaceutical supply chain against a variety of issues such as counterfeit, diverted, substandard, adulterated, misbranded and/or expired medications. Acsis' serialization solution includes Line Management, Site Management and Serial Aggregation Management capabilities. Collectively, this suite of solutions will ensure compliance with state and federal laws, including:

  • Automating and managing the application of serialized codes on packaging lines
  • Tracking and controlling all parent-to-child relationships
  • Providing real-time access to real-time and historical posting reports, reconciliation reports and serial number status reports
  • Supporting commissioning, de-commissioning, aggregation and de-aggregated events as required, regardless of component hierarchy

Acsis also will provide seamless, pre-built integration with SAP Auto-ID Infrastructure (AII) and Object Event Repository (OER) to share and track real-time product data throughout the supply chain.

"We are proud to partner with Daiichi Sankyo on this important project," said Neil Thall, Acsis CEO. "The Acsis serialization solution provides pharmaceutical companies with the necessary compliance capabilities to ensure consumer safety, in addition to establishing a foundation for achieving product visibility in the warehouse and across the supply chain."

About Daiichi Sankyo Inc.The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

About Acsis Inc.Acsis is the market leader for Enterprise Serialization in the Pharmaceutical, Food & Beverage and Industrial markets. With 30 years of proven experience and industry expertise, Acsis offers the only serialization solution that gives customers complete control to track and trace products throughout the supply chain to meet mandates, gain visibility and improve productivity, while reducing chargebacks and counterfeiting. For more information, visit www.acsisinc.com.

Contact: Renee TruttmanAcsis, Inc. Renee.truttmann@acsisinc.com760-201-6243

SOURCE Acsis Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs